Sugi Predict

Sugi Predict / Compounds / SCHEMBL4051746

SCHEMBL4051746

SCHEMBL4051746

Cc1cc(C(N)=O)n(N)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.36
▸ CDK8 P49336 2/20 0.36
▸ CCNC P24863 1/20 0.36
▸ PARP15 Q460N3 1/20 0.33
▸ PARP10 Q53GL7 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ RET P07949 1/20 0.33
▸ LTK P29376 1/20 0.33
▸ CSNK1A1 P48729 1/20 0.33
▸ CLK2 P49760 1/20 0.33
▸ CDK5 Q00535 1/20 0.33
▸ ACVR1 Q04771 1/20 0.33
▸ CLK4 Q9HAZ1 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ BRD4 O60885 1/20 0.31
▸ BRD9 Q9H8M2 1/20 0.31
▸ NNMT P40261 1/20 0.31
▸ TLR8 Q9NR97 1/20 0.30
▸ PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27479237 0.83 TPMT (0.38) —
SCHEMBL10002537 0.78 CDK8 (0.51) PARP1CDK8CCNCPARP15PARP10
SCHEMBL26062137 0.78 PARP1 (0.36) PARP1CDK8CCNCPARP15PARP10
SCHEMBL20859665 0.78 TDP1 (0.39) LMNA
SCHEMBL1298541 0.74 PARP1 (0.36) PARP1CDK8CCNC
SCHEMBL22828749 0.74 PARP1 (0.36) PARP1CDK8CCNC
SCHEMBL1298662 0.74 MAPK1 (0.38) PARP1CDK8CCNCLMNAPKM
SCHEMBL1299358 0.71 CA12 (0.41) LMNA
SCHEMBL17868541 0.70 CCNC (0.31) PARP1CDK8CCNC
SCHEMBL25899688 0.69 RAPGEF4 (0.33) PARP1CDK8CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795171-B2 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2023-10-24 — — US disclosed
US-11795171-B2 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2023-10-24 — — US disclosed
US-11795171-B2 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2023-10-24 — — US disclosed
EP-3988551-A1 CDK KINASE INHIBITOR Beijing Benicall Biotech Co., Ltd. (CN) 2022-04-27 — — EP disclosed
US-20220033403-A1 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2022-02-03 — — US disclosed
US-20220033403-A1 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2022-02-03 — — US disclosed
US-10981915-B2 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-04-20 — — US disclosed
US-10981915-B2 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-04-20 — — US disclosed
US-20190308980-A1 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2019-10-10 — — US disclosed
US-20190308980-A1 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2019-10-10 — — US disclosed
US-7244733-B2 Pyrrolotriazine inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-17 — — US disclosed
US-7112675-B2 Pyrrolotriazine inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-26 — — US disclosed
US-20060128709-A1 Pyrrolotriazine inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY 2006-06-15 — — US disclosed
EP-1669071-A1 Pyrrolotriazine inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-06-14 — — EP disclosed
EP-1183033-B1 PYRROLOTRIAZINE INHIBITORS OF KINASES BRISTOL MYERS SQUIBB CO (US) 2006-03-01 — — EP disclosed
US-20060004007-A1 Pyrrolotriazine inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY 2006-01-05 — — US disclosed
US-6982265-B1 Pyrrolotriazine inhibitors of kinases BRISTOL MYERS SQUIBB COMPANY (US) 2006-01-03 — — US disclosed
EP-1183033-A4 PYRROLOTRIAZINE INHIBITORS OF KINASES BRISTOL MYERS SQUIBB CO (US) 2002-07-17 — — EP disclosed
EP-1183033-A1 PYRROLOTRIAZINE INHIBITORS OF KINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-03-06 — — EP disclosed
WO-2000071129-A1 PYRROLOTRIAZINE INHIBITORS OF KINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2000-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981915-B2 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors USP7, UBA7, PSMB7 PARP1 1141/4885CDK8 456/4885CCNC 726/4885
US-20190308980-A1 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, PSMB7 PARP1 1141/4885CDK8 456/4885CCNC 726/4885
US-20220033403-A1 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, PSMB7 PARP1 1141/4885CDK8 456/4885CCNC 726/4885
US-20060128709-A1 Pyrrolotriazine inhibitors of kinases FGFR1, FGFR2, ERBB2 PARP1 677/4885CDK8 636/4885CCNC 1212/4885
US-20060004007-A1 Pyrrolotriazine inhibitors of kinases FGFR1, FGFR2, ERBB2 PARP1 677/4885CDK8 636/4885CCNC 1212/4885
US-11795171-B2 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors USP7, UBA7, PSMB7 PARP1 1141/4885CDK8 456/4885CCNC 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.